c-Cbl inhibition improves cardiac function and survival in response to myocardial ischemia
Khadija Rafiq1, Mikhail A Kolpakov1, Rachid Seqqat1
1From the Cardiovascular Research Center and Department of Physiology, Temple University School of Medicine, Philadelphia, PA (K.R., M.A.K., R.S., J.G., X.G., Z.Q., D.Y., S.R.H., A. Sabri); Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha (B.M., N.Z., W.A., H.B.); and Department of Surgery, University of Connecticut Health Center, Farmington (A. Sanjay).
Background:
The proto-oncogene Casitas b-lineage lymphoma (c-Cbl) is an adaptor protein with an intrinsic E3 ubiquitin ligase activity that targets receptor and nonreceptor tyrosine kinases, resulting in their ubiquitination and downregulation. However, the function of c-Cbl in the control of cardiac function is currently unknown. In this study, we examined the role of c-Cbl in myocyte death and cardiac function after myocardial ischemia.
Methods And Results:
We show increased c-Cbl expression in human ischemic and dilated cardiomyopathy hearts and in response to pathological stress stimuli in mice. c-Cbl-deficient mice demonstrated a more robust functional recovery after myocardial ischemia/reperfusion injury and significantly reduced myocyte apoptosis and improved cardiac function. Ubiquitination and downregulation of key survival c-Cbl targets, epidermal growth factor receptors and focal adhesion kinase, were significantly reduced in c-Cbl knockout mice. Inhibition of c-Cbl expression or its ubiquitin ligase activity in cardiac myocytes offered protection against H2O2 stress. Interestingly, c-Cbl deletion reduced the risk of death and increased cardiac functional recovery after chronic myocardial ischemia. This beneficial effect of c-Cbl deletion was associated with enhanced neoangiogenesis and increased expression of vascular endothelial growth factor-a and vascular endothelial growth factor receptor type 2 in the infarcted region.
Conclusions:
c-Cbl activation promotes myocyte apoptosis, inhibits angiogenesis, and causes adverse cardiac remodeling after myocardial infarction. These findings point to c-Cbl as a potential therapeutic target for the maintenance of cardiac function and remodeling after myocardial ischemia.
Insights
Casitas b-lineage lymphoma (c-Cbl) protein promotes heart cell death and hinders recovery after heart attacks. Inhibiting c-Cbl improves cardiac function and survival following myocardial ischemia.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Oncogene Signaling
Background:
- Casitas b-lineage lymphoma (c-Cbl) is an E3 ubiquitin ligase involved in protein downregulation.
- Its role in cardiac function and response to ischemia is not well understood.
Purpose of the Study:
- To investigate the function of c-Cbl in myocyte apoptosis and cardiac function after myocardial ischemia.
Main Methods:
- Examined c-Cbl expression in human heart disease and mouse models.
- Utilized c-Cbl-deficient mice to assess cardiac function post-ischemia/reperfusion.
- Measured myocyte apoptosis, protein ubiquitination, and neoangiogenesis.
Main Results:
- Increased c-Cbl expression observed in human cardiomyopathies and under stress.
- c-Cbl deficiency improved cardiac recovery, reduced apoptosis, and enhanced survival post-ischemia.
- Reduced ubiquitination of survival targets and increased angiogenesis were noted in c-Cbl knockout mice.
Conclusions:
- c-Cbl activation contributes to myocyte apoptosis, impaired angiogenesis, and adverse cardiac remodeling.
- Targeting c-Cbl may offer a therapeutic strategy for improving cardiac function after myocardial infarction.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
05:04In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
Published on: February 22, 2022
Related Concept Videos
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: β-Blockers
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy V: Interprofessional Care
Heart Failure Drugs: Inotropic Agents
